Plain-English translation of NCT06115135 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing — a medication that works by encouraging cancer cells to die — combined with two other drugs (isatuximab and dexamethasone) in patients with multiple myeloma that has stopped responding to previous treatments. The treatment is specifically designed for patients whose cancer cells carry a genetic change called t(11;14), which makes them more likely to respond to this type of therapy.
Multiple myeloma is a blood cancer that often becomes resistant to treatment over time, leaving patients with limited options. This trial is exploring whether combining this medication with two others might work better than single drugs alone for patients whose cancer has become hard to treat.
You likely qualify if…
You likely don't qualify if…
You would take by mouth daily and receive two other medications by infusion or injection on specific days of each 28-day treatment cycle. The trial will monitor your safety and how well the treatment works through blood tests, imaging scans, and regular clinic visits. You would continue treatment as long as the medication is helping and you are tolerating it well.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Oncotherapeutics
Enrollment target
~39 participants
Started
June 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Richard Bailey
Oncotherapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.